Infographics
-
Outsourcing Drivers By Company Size
2/25/2019
In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%).
-
Most Difficult Aspects Of Biosimilar Manufacturing
1/14/2019
Research firm ISR asked 109 respondents who are responsible for outsourcing biologic API to hypothesize what would be the most difficult aspect of manufacturing a biosimilar.
-
How Experience & Capacity Influence Biologic API Outsourcing
12/4/2018
In Q2, 2018, ISR asked 48 outsourcers of biologic API to select from four different reasons that manufacturing is split between in-house and external resources.
-
What Factors Influence Outsourcing Model Changes
12/4/2018
In Q2, 2018, ISR asked 100 people who outsource manufacturing to describe a scenario that has led or would lead their organization to change outsourcing models.
-
Outsourcing Impact Of Focus On Innovative Treatment
11/15/2018
In Q4, 2017, ISR asked a follow-up question to respondents who agreed that their company’s focus on developing new innovative treatments will impact its outsourcing practices.
-
Change Of Focus For Biopharma Manufacturers
11/15/2018
In Q4, 2017, ISR asked 730 buyers of outsourced manufacturing services about upcoming changes to their pipeline and how it might impact their outsourcing practices.
-
Projected Biologics Portfolios In 2023
10/12/2018
In Q2, 2018 ISR surveyed 100 outsourcers of bioprocessing / biologic API manufacturing to learn what they predict their company’s biologics portfolio will look like five years from now.
-
What Will Drive Biologics Market Growth?
8/8/2018
In Q2,2018, ISR surveyed drug innovators who outsource bioprocessing/biologic API manufacturing to learn their thoughts on what will have the greatest impact on market growth over the next five years.
-
Small Molecule Outsourcing Drivers
7/16/2018
In Q42017, ISR surveyed sponsors who outsource small molecule API and small molecule drug product manufacturing to inquire about their company’s main driver for working with contract manufacturers.
-
Small Molecule API Contract Manufacturer Loyalty
6/25/2018
In Q42017, ISR surveyed 227 sponsors who outsource small molecule API to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derive from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.